Edwards Lifesciences (EW) Tops Q3 EPS by 8c; Issues Solid Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Edwards Lifesciences (EW) PT Lifted to $130 at Piper Jaffray on 'Spectacular' Q3
October 24, 2014 7:59 AM EDTPiper Jaffray analyst Brooks West reiterated an Overweight rating and boosted his price target on Edwards Lifesciences (NYSE: EW) to $130.00 (from $120.00) following a "spectacular" Q3 beat on 44% underlying global TAVR sales growth with strength in both the US and OUS.
West commented,... More
